Completed PHASE1 INTERVENTIONAL 10-arm NCT03590600

A Single Ascending Dose Study of BTZ043

A Randomized, Double Blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Doses of BTZ043 in Healthy Adult Volunteers

Sponsor: German Center for Infection Research

Conditions Bacterial Infections Lung Diseases Mycobacterium Infections Tuberculosis Tuberculosis, Pulmonary

Interventions BTZ-043 Placebo

Updated 6 times since 2018 Last updated: Mar 6, 2019 Started: Jun 7, 2018 Primary completion: Aug 14, 2018 Completion: Mar 5, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03590600, this PHASE1 trial focuses on Bacterial Infections and Lung Diseases and remains completed. Sponsored by German Center for Infection Research, it has been updated 6 times since 2018, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Dec 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Aug 2018 — Dec 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

German Center for Infection Research
German Federal Ministry of Education and Research
Hans Knöll Institute (HKI)
Michael Hoelscher

Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Neu-Ulm, Germany